UBS Group
RVLP

UBS Group’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

UBS Group’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,708
Closed -$1.37K – 10510
2023
Q3 		$1.37K Buy
15,708
+15,483
+6,881% +$4.46K ﹤0.01% 7966
2023
Q2 		$126 Hold
225
– – ﹤0.01% 8471
2023
Q1 		$257 Sell
225
-1,157
-84% -$1.39K ﹤0.01% 9113
2022
Q4 		$1.55K Sell
1,382
-10,012
-88% -$16K ﹤0.01% 9845
2022
Q3 		$23K Buy
11,394
+11,169
+4,964% +$21.7K ﹤0.01% 7228
2022
Q2 		$0 Hold
225
– – ﹤0.01% 11309
2022
Q1 		$0 Sell
225
-2,547
-92% -$3.64K ﹤0.01% 11221
2021
Q4 		$3K Sell
2,772
-2,216
-44% -$3.6K ﹤0.01% 9727
2021
Q3 		$15K Buy
4,988
+3,289
+194% +$11.1K ﹤0.01% 7532
2021
Q2 		$5K Buy
+1,699
New +$5.2K ﹤0.01% 8597
2020
Q4 		– Sell
-600
Closed -$3K – 8911
2020
Q3 		$3K Buy
+600
New +$3.46K ﹤0.01% 7588
2020
Q1 		– Sell
-4,565
Closed -$32K – 8555
2019
Q4 		$32K Sell
4,565
-2,991
-40% -$16K ﹤0.01% 6604
2019
Q3 		$29K Buy
7,556
+6,087
+414% +$20.6K ﹤0.01% 6516
2019
Q2 		$6K Buy
+1,469
New +$4.88K ﹤0.01% 7340
2019
Q1 		– Sell
-3,602
Closed -$28K – 8310
2018
Q4 		$28K Buy
+3,602
New +$28.8K ﹤0.01% 6543

Other funds holding RVLP

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

UBS Group's RVLP Position: Q4 2023 in Review

UBS Group sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 15,708 shares — an estimated $1.37K sold.

UBS Group first reported a position in RVLP in Q4 2018 and held it in 15 quarters. The position peaked at $32K in Q4 2019. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

  • UBS Group reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 15,708 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023, an estimated $1.37K.
  • UBS Group first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 15 quarters.
  • UBS Group's RVL Pharmaceuticals plc Ordinary Shares position peaked at $32K in Q4 2019.
  • 3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.